<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7103671/results/search/disease/results.xml">
  <result pre="Research InstituteIndia[f], Center of Research Excellence on Therapeutic Proteins and" exact="Antibody" post="Engineering, Department of Parasitology, Faculty of Medicine Siriraj Hospital,"/>
  <result pre="PMC, consistent with existing copyright protections.KHVI_0_1735227.pdf Abstract ABSTRACT The novel" exact="coronavirus infection" post="(COVID-19 or Coronavirus disease 2019) that emerged from Wuhan,"/>
  <result pre="consistent with existing copyright protections.KHVI_0_1735227.pdf Abstract ABSTRACT The novel coronavirus" exact="infection" post="(COVID-19 or Coronavirus disease 2019) that emerged from Wuhan,"/>
  <result pre="copyright protections.KHVI_0_1735227.pdf Abstract ABSTRACT The novel coronavirus infection (COVID-19 or" exact="Coronavirus disease" post="2019) that emerged from Wuhan, Hubei province of China"/>
  <result pre="protections.KHVI_0_1735227.pdf Abstract ABSTRACT The novel coronavirus infection (COVID-19 or Coronavirus" exact="disease" post="2019) that emerged from Wuhan, Hubei province of China"/>
  <result pre="have been made to develop vaccines against human coronavirus (CoV)" exact="infections" post="such as MERS and SARS in the past decades."/>
  <result pre="progressed to randomized animal or human trials, hence may have" exact="limited" post="use to counter COVID-19 infection. This article highlights ongoing"/>
  <result pre="MERS-CoVs, which together could enable efforts to halt this emerging" exact="virus infection." post="KEYWORDS Emerging coronavirus COVID-19 vaccines therapeutics drugs Funding stated"/>
  <result pre="it was found to be the sister virus of severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV).1 The ongoing coronavirus threat that"/>
  <result pre="was found to be the sister virus of severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV).1 The ongoing coronavirus threat that emerged"/>
  <result pre="found to be the sister virus of severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV).1 The ongoing coronavirus threat that emerged in"/>
  <result pre="efforts have been directed to develop vaccines against human CoV" exact="infections" post="in recent decades, but a limiting factor is the"/>
  <result pre="care including oxygen therapy, fluid therapy, and antibiotics for treating" exact="secondary" post="bacterial infections. The WHO also recommends the isolation of"/>
  <result pre="including oxygen therapy, fluid therapy, and antibiotics for treating secondary" exact="bacterial infections." post="The WHO also recommends the isolation of patients suspected"/>
  <result pre="plasma, and mAbs.17 Nevertheless, before utilizing these drugs for COVID-19" exact="pneumonia" post="patients, clinical efficacy, and safety studies should be conducted."/>
  <result pre="in the right direction to halt this emerging virus. Vaccines" exact="Multiple" post="strategies are adopted in the development of CoV vaccines;"/>
  <result pre="domain (RBD) and expression in virus-like particles (VLP), DNA, or" exact="viral" post="vectors5,9,18-21 The S protein molecule contains two subunits, S1"/>
  <result pre="fusion between the virus and host cell membranes for releasing" exact="viral" post="RNA into the cytoplasm for replication.19 Hence, S-protein-based vaccines"/>
  <result pre="Hence, S-protein-based vaccines should induce antibodies that block not only" exact="viral" post="receptor binding but also virus genome uncoating. It has"/>
  <result pre="a major role in the induction of protective immunity during" exact="infection" post="with SARS-CoV by eliciting neutralizing-antibodies and T-cell responses.19 Thus,"/>
  <result pre="SARS-CoV vaccines.18 Recombinant adenovirus-based vaccine expressing MERS-CoV S protein induces" exact="systemic" post="IgG, secretory IgA, and lung-resident memory T-cell responses when"/>
  <result pre="suggesting that the vaccine may confer protection against MERS-CoV.24 Furthermore," exact="rabies" post="virus (RV) as a viral vector as well as"/>
  <result pre="confer protection against MERS-CoV.24 Furthermore, rabies virus (RV) as a" exact="viral" post="vector as well as Gram-positive enhancer matrix (GEM) as"/>
  <result pre="vector as well as Gram-positive enhancer matrix (GEM) as a" exact="bacterial" post="vector has been used to express MERS-CoV S protein."/>
  <result pre="14 (nsp14) or to delete the envelope protein in SARS.5" exact="Avian" post="infectious bronchitis virus (IBV) is a chicken CoV. It"/>
  <result pre="(nsp14) or to delete the envelope protein in SARS.5 Avian" exact="infectious" post="bronchitis virus (IBV) is a chicken CoV. It was"/>
  <result pre="or to delete the envelope protein in SARS.5 Avian infectious" exact="bronchitis" post="virus (IBV) is a chicken CoV. It was suggested"/>
  <result pre="develop a chimpanzee adenovirus-vectored COVID-19 vaccine candidate.35 The Coalition for" exact="Epidemic" post="Preparedness Innovations (CEPI) recently announced the initiation of three"/>
  <result pre="2019 to develop the molecular clamp vaccine platform against multiple" exact="viral" post="pathogens including MERS-CoV ($10 M funding). The vaccine platform"/>
  <result pre="MERS-CoV ($10 M funding). The vaccine platform functions by synthesizing" exact="viral" post="surface proteins that get attached to the host cells"/>
  <result pre="Research Center (VRC) of the National Institute of Allergy and" exact="Infectious" post="Diseases (NIAID), a part of the National Institutes of"/>
  <result pre="Center (VRC) of the National Institute of Allergy and Infectious" exact="Diseases" post="(NIAID), a part of the National Institutes of Health"/>
  <result pre="of virus replication. Examples include trans bodies to influenza virus," exact="hepatitis" post="C virus, Ebola virus, and Dengue virus.41 Thus, it"/>
  <result pre="bodies to influenza virus, hepatitis C virus, Ebola virus, and" exact="Dengue" post="virus.41 Thus, it is possible to generate trans bodies"/>
  <result pre="Development of an efficient animal model that mimics the clinical" exact="disease" post="can inform on pathogenesis as well as to develop"/>
  <result pre="due to the inability of MERS-CoV to replicate in the" exact="respiratory" post="tracts of these species. Small animals (mice or hamsters)"/>
  <result pre="of these species. Small animals (mice or hamsters) resisting natural" exact="infection" post="with MERS-CoVs (which are susceptible to SARS-CoV) have been"/>
  <result pre="and hDPP4-Tg mice (transgenic for expressing hDPP4), and ascertained for" exact="susceptibility to" post="MERS-CoV infection.55 Alteration in the mouse genome using the"/>
  <result pre="CRISPR-Cas9 gene-editing tool could make the animals susceptible to CoV" exact="infection" post="and virus replication.56 Genetic engineering was used in the"/>
  <result pre="animals such as mice and rabbits are preferred due to" exact="lower" post="cost, ease of manipulation, and readily available efficacy methods.43"/>
  <result pre="emerging SARS-CoV-2 by identifying receptor affinity of SARS-CoV-2 and studying" exact="disease" post="manifestations, pathologies/viral pathogenesis associated with experimental inoculation of the"/>
  <result pre="culture systems Several permissive cell lines to hCoVs including monkey" exact="epithelial" post="cell lines (LLC-MK2 and Vero-B4) have been used in"/>
  <result pre="hepatoma cell lines, targeted by neutralizing antibodies in virus-infected patients.59" exact="Advanced" post="ex–vivo 3D tracheobronchial tissue (mimicking epithelium of conductive airway)"/>
  <result pre="has been attempted in Vero and the Huh-7 cells (human" exact="liver cancer" post="cells).63 Pseudotyped virions/VLPs encoding reporter systems such as GFP"/>
  <result pre="been attempted in Vero and the Huh-7 cells (human liver" exact="cancer" post="cells).63 Pseudotyped virions/VLPs encoding reporter systems such as GFP"/>
  <result pre="be performed in BSL-2 facility since these do not use" exact="infectious" post="virus. A safety concern for passive immunization with antibodies"/>
  <result pre="and antiviral inhibitors. Data from animal CoV vaccination suggest that" exact="systemic" post="humoral or cell-mediated immune responses induced by parenteral administration"/>
  <result pre="induced by parenteral administration may not be adequate to prevent" exact="respiratory" post="tract infection.66 Because respiratory mucosa is the initial site"/>
  <result pre="may not be adequate to prevent respiratory tract infection.66 Because" exact="respiratory" post="mucosa is the initial site in CoV infection and"/>
  <result pre="not be adequate to prevent respiratory tract infection.66 Because respiratory" exact="mucosa" post="is the initial site in CoV infection and transmission,"/>
  <result pre="infection.66 Because respiratory mucosa is the initial site in CoV" exact="infection" post="and transmission, mucosal immunization, such as using intranasal vaccine,67"/>
  <result pre="an effective strategy for prophylaxis by induction of mucosal and" exact="systemic" post="immune responses. The molecular mechanisms of mucosal and systemic"/>
  <result pre="and systemic immune responses. The molecular mechanisms of mucosal and" exact="systemic" post="immunological factors are different, such that it is difficult"/>
  <result pre="for protection as well as herd immunity toward different CoV" exact="infections" post="warrant detailed investigations. Therapeutics The main measure in clinical"/>
  <result pre="virus, molecules, or inhibitors that target specific enzymes involved in" exact="viral" post="replication and transcription, small-molecule inhibitors targeting helicase, essential proteases,"/>
  <result pre="the lack of randomized animal or human trials, hence of" exact="limited" post="use for COVID-19. Hence, the necessary support of extensive"/>
  <result pre="angiotensin type-1 receptor (AT1R) inhibitors might be able to reduce" exact="pulmonary" post="inflammatory responses, thereby reducing the mortality.72 The guidance to"/>
  <result pre="The main treatments such as mechanical ventilation, ICU admission, and" exact="symptomatic" post="and supportive care are recommended for severe cases. Furthermore,"/>
  <result pre="is to repurpose broadly acting antiviral drugs used for other" exact="viral" post="infections. Such drugs have the advantage of easy availability,"/>
  <result pre="against COVID-19 since higher concentrations were required to reduce the" exact="viral infection" post="in vitro. Both remdesivir and chloroquine are being used"/>
  <result pre="COVID-19 since higher concentrations were required to reduce the viral" exact="infection" post="in vitro. Both remdesivir and chloroquine are being used"/>
  <result pre="preventive and control measures that minimize the risk of possible" exact="disease" post="transmission. Results obtained from the recently conducted in vitro"/>
  <result pre="these drugs much easier. S protein is considered a key" exact="viral" post="antigen for developing CoV vaccines, as shown in several"/>
  <result pre="de GrootRJ, DrostenC, GulyaevaAA, HaagmansBL, LauberC, LeontovichAM, NeumanBW, et alSevere" exact="acute" post="respiratory syndrome-related coronavirus: the species and its viruses–a statement"/>
  <result pre="GrootRJ, DrostenC, GulyaevaAA, HaagmansBL, LauberC, LeontovichAM, NeumanBW, et alSevere acute" exact="respiratory" post="syndrome-related coronavirus: the species and its viruses–a statement of"/>
  <result pre="inhibitors. Acta Pharm. 2020;70(2):145–59. doi:10.2478/acph-2020-0024.31955138 16.collab: WHOClinical management of severe" exact="acute" post="respiratory infection when novel coronavirus (nCoV) infection is suspected;"/>
  <result pre="Acta Pharm. 2020;70(2):145–59. doi:10.2478/acph-2020-0024.31955138 16.collab: WHOClinical management of severe acute" exact="respiratory" post="infection when novel coronavirus (nCoV) infection is suspected; 2020[accessed"/>
  <result pre="Pharm. 2020;70(2):145–59. doi:10.2478/acph-2020-0024.31955138 16.collab: WHOClinical management of severe acute respiratory" exact="infection" post="when novel coronavirus (nCoV) infection is suspected; 2020[accessed 2020"/>
  <result pre="management of severe acute respiratory infection when novel coronavirus (nCoV)" exact="infection" post="is suspected; 2020[accessed 2020 215]https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected 17.LiH, WangYM, XuJY, CaoBPotential"/>
  <result pre="LamirandeEW, MurphyBR, SubbaraoK, CollinsPLContributions of the structural proteins of severe" exact="acute" post="respiratory syndrome coronavirus to protective immunity. Proc Natl Acad"/>
  <result pre="MurphyBR, SubbaraoK, CollinsPLContributions of the structural proteins of severe acute" exact="respiratory" post="syndrome coronavirus to protective immunity. Proc Natl Acad Sci"/>
  <result pre="SubbaraoK, CollinsPLContributions of the structural proteins of severe acute respiratory" exact="syndrome" post="coronavirus to protective immunity. Proc Natl Acad Sci U"/>
  <result pre="recombinant adenovirus-based vaccine expressing full-length spike protein of Middle East" exact="respiratory" post="syndrome coronavirus. PLoS One. 2019;14(7):e0220196. doi:10.1371/journal.pone.0220196.31329652 25.LiuWJ, ZhaoM, LiuK,"/>
  <result pre="adenovirus-based vaccine expressing full-length spike protein of Middle East respiratory" exact="syndrome" post="coronavirus. PLoS One. 2019;14(7):e0220196. doi:10.1371/journal.pone.0220196.31329652 25.LiuWJ, ZhaoM, LiuK, XuK,"/>
  <result pre="Antiviral Res. 2017;137:82–92. doi:10.1016/j.antiviral.2016.11.006.27840203 26.JiangS, DuL, ShiZAn emerging coronavirus causing" exact="pneumonia" post="outbreak in Wuhan, China: calling for developing therapeutic and"/>
  <result pre="doi:10.1080/22221751.2020.1723441. 27.YuF, DuL, OjciusDM, PanC, JiangSMeasures for diagnosing and treating" exact="infections" post="by a novel coronavirus responsible for a pneumonia outbreak"/>
  <result pre="and treating infections by a novel coronavirus responsible for a" exact="pneumonia" post="outbreak originating in Wuhan, China. Microbes Infect. 2020S1286-4579(20)30025–3. doi:10.1016/j.micinf.2020.01.003."/>
  <result pre="the past: possible urgent prevention and treatment options for severe" exact="acute" post="respiratory infections caused by 2019-nCoV. Chembiochem. 2020. doi:10.1002/cbic.202000047. 29.VeljkovicV,"/>
  <result pre="past: possible urgent prevention and treatment options for severe acute" exact="respiratory" post="infections caused by 2019-nCoV. Chembiochem. 2020. doi:10.1002/cbic.202000047. 29.VeljkovicV, Vergara-AlertJ,"/>
  <result pre="possible urgent prevention and treatment options for severe acute respiratory" exact="infections" post="caused by 2019-nCoV. Chembiochem. 2020. doi:10.1002/cbic.202000047. 29.VeljkovicV, Vergara-AlertJ, SegalésJ,"/>
  <result pre="highly pathogenic MERS-CoV: an in silico approach applied to emerging" exact="infectious diseases." post="PLoS One. 2015;10(12):e0144475. doi:10.1371/journal.pone.0144475.26641892 32.XieQ, HeX, YangF, LiuX, LiY,"/>
  <result pre="of B-cell epitopes of the envelope protein of Middle East" exact="respiratory" post="syndrome-coronavirus. IEEE/ACM Trans Comput Biol Bioinform. 2018;15(4):1344–50. doi:10.1109/TCBB.2017.2702588.28574363 33.BijlengaGProposal"/>
  <result pre="2018;15(4):1344–50. doi:10.1109/TCBB.2017.2702588.28574363 33.BijlengaGProposal for vaccination against SARS coronavirus using avian" exact="infectious" post="bronchitis virus strain H from The Netherlands. J Infect."/>
  <result pre="doi:10.1109/TCBB.2017.2702588.28574363 33.BijlengaGProposal for vaccination against SARS coronavirus using avian infectious" exact="bronchitis" post="virus strain H from The Netherlands. J Infect. 2005;51(3):263–65."/>
  <result pre="doi:10.1016/j.jinf.2005.04.010. 34.ZhangL, LiuYPotential interventions for novel coronavirus in China: a" exact="systemic" post="review. J Med Virol. 2020. doi:10.1002/jmv.25707. 35.collab: NIAIDDeveloping therapeutics"/>
  <result pre="HoKL, TanWSRecent advances in the vaccine development against Middle East" exact="respiratory" post="syndrome-coronavirus. Front Microbiol. 2019;10:1781. doi:10.3389/fmicb.2019.01781.31428074 44.MartinaBE, HaagmansBL, KuikenT, FouchierRA,"/>
  <result pre="HaagmansBL, KuikenT, FouchierRA, RimmelzwaanGF, Van AmerongenG, PeirisJS, LimW, OsterhausADVirology: SARS" exact="virus infection" post="of cats and ferrets. Nature. 2003;425(6961):915. doi:10.1038/425915a.14586458 45.RobertsA, WoodJ,"/>
  <result pre="KuikenT, FouchierRA, RimmelzwaanGF, Van AmerongenG, PeirisJS, LimW, OsterhausADVirology: SARS virus" exact="infection" post="of cats and ferrets. Nature. 2003;425(6961):915. doi:10.1038/425915a.14586458 45.RobertsA, WoodJ,"/>
  <result pre="SheahanT, ShiehWJ, ZakiSR, BaricR, EnjuanesL, et alA live attenuated severe" exact="acute" post="respiratory syndrome coronavirus is immunogenic and efficacious in golden"/>
  <result pre="ShiehWJ, ZakiSR, BaricR, EnjuanesL, et alA live attenuated severe acute" exact="respiratory" post="syndrome coronavirus is immunogenic and efficacious in golden Syrian"/>
  <result pre="ZakiSR, BaricR, EnjuanesL, et alA live attenuated severe acute respiratory" exact="syndrome" post="coronavirus is immunogenic and efficacious in golden Syrian hamsters."/>
  <result pre="et alRapid generation of a mouse model for Middle East" exact="respiratory" post="syndrome. Proc Natl Acad Sci U S A. 2014;111(13):4970–75."/>
  <result pre="for human angiotensin-converting enzyme 2 provide a model for SARS" exact="coronavirus infection." post="Comp Med. 2007;57:450–59.17974127 52.MunsterVJ, de WitE, FeldmannHPneumonia from human"/>
  <result pre="van DoremalenN, HaddockE, NagyL, et alInfection with MERS-CoV causes lethal" exact="pneumonia" post="in the common marmoset. PLoS Pathog. 2014;10(8):e1004250. doi:10.1371/journal.ppat.1004250.25144235 54.MenacheryVD,"/>
  <result pre="BeallA, TangXC, MarascoWA, HeiseMT, BaricRSA mouse model for MERS coronavirus-induced" exact="acute respiratory distress syndrome." post="Nat Microbiol. 2016;2:16226. doi:10.1038/nmicrobiol.2016.226.27892925 57.LeistSR, CockrellASGenetically engineering a susceptible"/>
  <result pre="TangXC, MarascoWA, HeiseMT, BaricRSA mouse model for MERS coronavirus-induced acute" exact="respiratory" post="distress syndrome. Nat Microbiol. 2016;2:16226. doi:10.1038/nmicrobiol.2016.226.27892925 57.LeistSR, CockrellASGenetically engineering"/>
  <result pre="doi:10.1038/nmicrobiol.2016.226.27892925 57.LeistSR, CockrellASGenetically engineering a susceptible mouse model for MERS-CoV-induced" exact="acute respiratory distress syndrome." post="Methods Mol Biol. 2020;2099:137–59. doi:10.1007/978-1-0716-0211-9_12.31883094 58.EckerleI, CormanVM, MüllerMA, LenkM,"/>
  <result pre="57.LeistSR, CockrellASGenetically engineering a susceptible mouse model for MERS-CoV-induced acute" exact="respiratory" post="distress syndrome. Methods Mol Biol. 2020;2099:137–59. doi:10.1007/978-1-0716-0211-9_12.31883094 58.EckerleI, CormanVM,"/>
  <result pre="GrambergT, GeierM, KrumbiegelM, KuateS, UberlaK, NiedrigM, PöhlmannSS protein of severe" exact="acute" post="respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines"/>
  <result pre="GeierM, KrumbiegelM, KuateS, UberlaK, NiedrigM, PöhlmannSS protein of severe acute" exact="respiratory" post="syndrome-associated coronavirus mediates entry into hepatoma cell lines and"/>
  <result pre="CoderreJ, VasilievaN, HanZ, GreenoughTC, et alRetroviruses pseudotyped with the severe" exact="acute" post="respiratory syndrome coronavirus spike protein efficiently infect cells expressing"/>
  <result pre="VasilievaN, HanZ, GreenoughTC, et alRetroviruses pseudotyped with the severe acute" exact="respiratory" post="syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting"/>
  <result pre="HanZ, GreenoughTC, et alRetroviruses pseudotyped with the severe acute respiratory" exact="syndrome" post="coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme"/>
  <result pre="MizutaniT, SaijoM, KuraneI, TaguchiF, TashiroM, MorikawaSEvaluation of a novel vesicular" exact="stomatitis" post="virus pseudotype-based assay for detection of neutralizing antibody responses"/>
  <result pre="WangP, ZhangS, ShiX, WangX, ZhangLAntibodies and vaccines against Middle East" exact="respiratory" post="syndrome coronavirus. Emerg Infect Dis. 2019;8(1):841–56. doi:10.1080/22221751.2019.1624482. 66.QuD, ZhengB,"/>
  <result pre="ZhangS, ShiX, WangX, ZhangLAntibodies and vaccines against Middle East respiratory" exact="syndrome" post="coronavirus. Emerg Infect Dis. 2019;8(1):841–56. doi:10.1080/22221751.2019.1624482. 66.QuD, ZhengB, YaoX,"/>
  <result pre="HongSP, KimK, ChoMW, KimE, SungMH, KimCJMucosal immunization with surface-displayed severe" exact="acute" post="respiratory syndrome coronavirus spike protein on Lactobacillus casei induces"/>
  <result pre="KimK, ChoMW, KimE, SungMH, KimCJMucosal immunization with surface-displayed severe acute" exact="respiratory" post="syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing"/>
  <result pre="ChoMW, KimE, SungMH, KimCJMucosal immunization with surface-displayed severe acute respiratory" exact="syndrome" post="coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies"/>
  <result pre="doi:10.1128/JVI.80.8.4079-4087.2006.16571824 68.AdedejiAO, SeversonW, JonssonC, SinghK, WeissSR, SarafianosSGNovel inhibitors of severe" exact="acute" post="respiratory syndrome coronavirus entry that act by three distinct"/>
  <result pre="68.AdedejiAO, SeversonW, JonssonC, SinghK, WeissSR, SarafianosSGNovel inhibitors of severe acute" exact="respiratory" post="syndrome coronavirus entry that act by three distinct mechanisms."/>
  <result pre="SeversonW, JonssonC, SinghK, WeissSR, SarafianosSGNovel inhibitors of severe acute respiratory" exact="syndrome" post="coronavirus entry that act by three distinct mechanisms. J"/>
  <result pre="macaques. Nat Med. 2013;19(10):1313–17. doi:10.1038/nm.3362.24013700 70.LuL, LiuQ, DuL, JiangSMiddle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV): challenges in identifying its source and"/>
  <result pre="Nat Med. 2013;19(10):1313–17. doi:10.1038/nm.3362.24013700 70.LuL, LiuQ, DuL, JiangSMiddle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV): challenges in identifying its source and controlling"/>
  <result pre="et alTreatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV" exact="infection" post="in a nonhuman primate model of common marmoset. J"/>
  <result pre="al.; collab: And the MIRACLE trial groupTreatment of Middle East" exact="respiratory" post="syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE"/>
  <result pre="collab: And the MIRACLE trial groupTreatment of Middle East respiratory" exact="syndrome" post="with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial):"/>
  <result pre="2020b;395:470–73. S0140-6736(20)30185-9. doi:10.1016/S0140-6736(20)30185-9.31986257 77.ChengVCC, WongSC, ToKKW, HoPL, YuenKYPreparedness and proactive" exact="infection" post="control measures against the emerging Wuhan coronavirus pneumonia in"/>
  <result pre="YuenKYPreparedness and proactive infection control measures against the emerging Wuhan" exact="coronavirus pneumonia" post="in China. J Hosp Infect. 2020:pii: S0195-6701(20)30034–7. doi:10.1016/j.jhin.2020.01.010."/>
  <result pre="and proactive infection control measures against the emerging Wuhan coronavirus" exact="pneumonia" post="in China. J Hosp Infect. 2020:pii: S0195-6701(20)30034–7. doi:10.1016/j.jhin.2020.01.010."/>
 </snippets>
</snippetsTree>
